Target type: biologicalprocess
Any process that modulates the frequency, rate or extent of the regulated release of growth hormone from a cell. [GOC:dph]
The regulation of growth hormone (GH) secretion is a complex process involving multiple factors, including hypothalamic hormones, feedback loops, and other hormones.
**Hypothalamic Control:**
* **Growth hormone-releasing hormone (GHRH):** GHRH, produced by the hypothalamus, is the primary stimulator of GH release from the anterior pituitary gland. It binds to GHRH receptors on somatotroph cells, activating a signaling pathway that ultimately leads to GH synthesis and release.
* **Somatostatin:** This inhibitory hormone, also produced by the hypothalamus, suppresses GH secretion. It binds to somatostatin receptors on somatotroph cells, counteracting the effects of GHRH.
**Feedback Loops:**
* **GH feedback:** GH itself exerts negative feedback on its own secretion. Elevated GH levels suppress GHRH release and stimulate somatostatin production, reducing further GH secretion. This helps maintain GH levels within a specific range.
* **Insulin-like growth factor 1 (IGF-1) feedback:** IGF-1, a hormone produced primarily by the liver in response to GH stimulation, also provides negative feedback. IGF-1 suppresses both GHRH release and GH synthesis.
**Other Factors:**
* **Stress:** Stressful situations can suppress GH secretion, possibly by stimulating somatostatin release.
* **Sleep:** GH secretion is highest during deep sleep, likely due to reduced somatostatin release.
* **Nutrition:** Nutritional status can influence GH secretion. Fasting and protein deficiency can increase GH levels, while adequate nutrition can suppress them.
* **Age:** GH secretion declines with age, contributing to age-related changes in body composition and function.
* **Gender:** Males tend to have higher GH levels than females.
* **Exercise:** Exercise can stimulate GH secretion, especially resistance training.
**Summary:** The regulation of GH secretion is a dynamic process involving a complex interplay of hypothalamic hormones, feedback mechanisms, and other factors. This intricate control ensures that GH levels are maintained within a specific range to support normal growth and development throughout life.'
"
Protein | Definition | Taxonomy |
---|---|---|
Growth hormone secretagogue receptor type 1 | A growth hormone secretagogue receptor that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q92847] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
substance p | peptide | neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent | |
l 692429 | L 692429: stimulates release of growth hormone; RN refers to (R)-isomer; structure given in first source | ||
l 163191 | |||
cp 424391 | CP 424391: a growth hormone secretagogue; structure in first source | ||
hexarelin | hexarelin: a synthetic growth hormone releasing peptide; structurally similar to GHRP-6, with the substitution of D-Trp with its 2-methyl derivative; more potent & stable and less toxic than GHRP-6 | ||
sm 130686 | SM 130686: a growth hormone secretagogue; structure in first source | ||
macimorelin | |||
tabimorelin | tabimorelin: a growth hormone secretagogue; structure in first source | ||
l 162752 | |||
sk&f 110679 | |||
ulimorelin | ulimorelin: ghrelin agonist; an 18-membered macrocycle containing 3 amide bonds and a secondary amine as well as 4 stereogenic centers; belongs to macrocyclic peptidomimetics | oligopeptide | |
n-(3-fluorophenyl)-1-((4-(((3s)-3-methyl-1-piperazinyl)methyl)phenyl)acetyl)-4-piperidinamine | N-(3-fluorophenyl)-1-((4-(((3S)-3-methyl-1-piperazinyl)methyl)phenyl)acetyl)-4-piperidinamine: a small molecule motilin receptor agonist; structure in first source | acetamides | |
yil 781 | YIL 781: an appetite suppressant and weight loss promoter; structure in first source | ||
nitd 609 | NITD 609: an antimalarial and coccidiostat; structure in first source | ||
gsk 2334470 | GSK 2334470: a PDK1 inhibitor; structure in first source | indazoles |